2 Nuclear Energy Stocks to Buy in May

The U.S. aims to quadruple nuclear capacity from about 100 GW in 2024 to 400 GW by 2050, a major tailwind for uranium and small modular reactor suppliers. Cameco is highlighted as a key uranium beneficiary, producing about 17% of global uranium in 2024 and owning a 49% stake in Westinghouse, which is tied to an $80 billion U.S. reactor agreement. NuScale Power is presented as a high-risk SMR play with NRC approval but no commercial U.S. reactors yet, limiting near-term upside despite long-duration growth potential.

Analysis

The key second-order trade is not just “nuclear up,” but a widening spread between fuel leverage and execution leverage. CCJ is the cleaner, earlier monetization vehicle because supply is structurally tight and contracting visibility should improve before new capacity does; the market can underwrite higher uranium pricing well before any new reactor gets built. SMR, by contrast, is a classic “option on policy + capex cycle” story: enormous theoretical upside if first-of-a-kind projects land, but the equity is still hostage to financing, permitting, and schedule slippage.

The market is likely underappreciating how AI power demand changes the buyer base. If hyperscalers and utilities start treating nuclear as load-following infrastructure rather than a purely grid-scale baseload asset, demand shifts from long-duration utility procurement to faster decision cycles driven by data-center expansion. That favors incumbents with existing regulatory relationships and fuel supply, while pressuring smaller developers that need several layers of capital and policy coordination before revenue appears.

Near-term, the biggest risk is that the trade gets crowded into a policy narrative faster than physical capacity can respond. That creates a set-up where uranium names can continue to rerate over months, but SMR equities are vulnerable to a “show me” phase once investors demand firm orders, not design wins. The catalyst to watch is not another endorsement headline; it is signed PPAs, fuel-cycle contracting, and any concrete federal procurement or loan-guarantee framework that converts rhetoric into bankable cash flows.

Contrarian take: consensus may be overestimating how quickly nuclear can solve AI power shortages, which could actually benefit the sector’s suppliers more than its developers. In that window, the market may keep paying for the scarcity of fuel and regulated expertise while discounting the long-dated engineering risk embedded in reactor designers. The cleaner expression is to own the bottleneck, not the promise.

Key Decisions for Investors

• Overweight CCJ on any pullback over the next 1-3 months; use it as the core nuclear expression because pricing power can re-rate ahead of actual megaproject deliveries. Risk/reward skews to the upside if uranium contract renewals tighten, with downside mainly tied to a broader risk-off or commodity correction.
• Treat SMR as a tactical call option, not a core hold: buy only on weakness after funding/award headlines, or express via small call spreads 6-12 months out. The thesis works only if first commercial commitments emerge; otherwise theta and financing dilution dominate.
• Pair trade: long CCJ / short a basket of pre-revenue clean-tech developers with similar AI-power exposure. This isolates the “bottleneck wins” thesis and reduces exposure to policy disappointment and capex delays.
• For event-driven accounts, buy 3-6 month out-of-the-money calls on CCJ into any new federal reactor/AI power announcement, but keep sizing modest. These catalysts can reprice the stock quickly, while the downside is limited to premium.
• Avoid chasing BAC, NVDA, or INTC on this headline alone; their direct sensitivity is narrative-level rather than earnings-level. If you want AI power exposure, the cleaner trade is CCJ over the next quarter, not semis or banks.